83 citations
,
October 2012 in “International Journal of Oncology” In this in vitro study, wedelolactone induced selective apoptosis in prostate cancer cells by inhibiting 5-Lox activity, suggesting it may have potential as a treatment for prostate cancer.
58 citations
,
March 2019 in “Frontiers in Pharmacology” This study found that wedelolactone from Eclipta prostrata L. significantly reduced lung inflammation and fibrosis in mice with bleomycin-induced pulmonary fibrosis, suggesting potential therapeutic benefits through AMPK activation.
53 citations
,
November 2014 in “International Journal of Oncology” This study found that wedelolactone, a natural compound from plants, inhibited breast cancer-mediated osteoclast differentiation and activity in vitro, suggesting its potential as a therapy for bone destruction in breast cancer bone metastasis.
6 citations
,
May 2018 in “Plant Cell, Tissue and Organ Culture (PCTOC)” This study found that adjusting plant growth conditions, such as the use of elicitors like yeast extract and methyl jasmonate, increased wedelolactone production in Eclipta alba cell suspension culture.
3 citations
,
November 2020 in “Phyton-international Journal of Experimental Botany” This review discusses the potential therapeutic applications of wedelolactone, a compound in Eclipta prostrata, for various chronic human diseases and reports no new clinical results.